Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28127175 | 0.77 | CUL4A (0.46) | MKNK1MKNK2NOS2ADORA2AADORA1 | |
| SCHEMBL25481828 | 0.77 | HRH3 (0.50) | HRH3HRH4ROCK1 | |
| SCHEMBL25481443 | 0.77 | HRH3 (0.50) | HRH3HRH4ROCK1 | |
| SCHEMBL25481832 | 0.77 | HRH3 (0.50) | HRH3HRH4ROCK1 | |
| SCHEMBL28127174 | 0.77 | CUL4A (0.46) | MKNK1MKNK2NOS2ADORA2AADORA1 | |
| SCHEMBL13018712 | 0.77 | HRH3 (0.53) | HRH3HRH4ROCK1 | |
| SCHEMBL13280212 | 0.76 | ITGB2 (0.45) | MKNK1MKNK2CHUKADORA2AADORA1 | |
| SCHEMBL13280367 | 0.76 | ITGB2 (0.45) | MKNK1MKNK2CHUKADORA2AADORA1 | |
| SCHEMBL13280214 | 0.76 | ITGB2 (0.45) | MKNK1MKNK2CHUKADORA2AADORA1 | |
| SCHEMBL15360083 | 0.76 | MKNK1 (0.46) | MKNK1MKNK2HRH4ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | UNIV VIRGINIA PATENT FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3962485-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | University Of Virginia Patent Foundation (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020223715-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVILACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213055-A1 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | VCL, VPS28, HDLBP | HRH3 3683/4885MKNK1 1500/4885MKNK2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.